Bullish case
$380 to $405
More likely if oncology, neuroscience, and cardiovascular products keep compounding, MedTech growth stays healthy, talc liability becomes more bounded, and investors pay a high-20s earnings multiple.
Johnson & Johnson research snapshot
JNJ AI Stock Analysis
JNJ AI stock analysis currently reads Johnson & Johnson as a high-quality healthcare compounder with strong Innovative Medicine and MedTech franchises, a larger oncology and neuroscience growth engine, meaningful free cash flow, and valuation that already prices in better execution. At the July 8, 2026 data cutoff, JNJ traded near $267.24 with an implied market capitalization of about $643.30 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$267.24
Market cap
$643.30 billion
AI score
76 / 100
Rating
High-quality healthcare compounder, valuation watch
Trend status
Strong technical trend near a 52-week high
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Johnson & Johnson has long public filings, detailed product and segment disclosures, quarterly releases, broad analyst coverage, and liquid market data.
- bias Check
- The main AI bias risk is over-weighting the visible quality, dividend record, and 2025 to 2026 growth recovery while under-weighting talc litigation, Stelara erosion, pipeline execution, MedTech separation risk, and valuation sensitivity.
- ai Confidence
- High for reported sales, EPS, free cash flow, market cap math, and quoted technical indicators. Medium for forward valuation because litigation outcomes, drug launches, patent cycles, and MedTech execution can change the earnings multiple quickly.
- investment Certainty
- Medium. The business quality is clearer than the margin of safety after the stock reached the upper end of its recent trading range.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Johnson & Johnson sells patented medicines and medical technologies across oncology, immunology, neuroscience, cardiovascular, surgery, and vision. | High |
| Moat | The moat comes from clinical evidence, patents, physician trust, hospital relationships, regulatory expertise, scale, and a wide global commercial footprint. | High |
| Management | Joaquin Duato is steering JNJ toward focused Innovative Medicine and MedTech growth while managing acquisitions, pipeline investment, dividends, litigation, and the planned orthopaedics separation. | Medium-high |
| Financial trend | FY2025 sales rose 6.0% to $94.193 billion, and Q1 2026 sales rose 9.9% to $24.062 billion with updated 2026 reported sales guidance near $100.8 billion at the midpoint. | High |
| Valuation | At $267.24, JNJ traded near 24.2x FY2025 diluted EPS, 23.1x updated 2026 adjusted EPS guidance, 6.8x sales per share, and 32.7x FY2025 free cash flow per share. | Medium-high |
| Technical trend | Daily technical signals were strong, with JNJ above major moving averages and near a 52-week high, while RSI readings were close to overbought territory. | Medium |
| Risk level | Key risks are talc litigation, patent loss and biosimilar pressure, R&D disappointment, acquisition integration, device-cycle execution, and multiple compression. | Medium-high |
| AI confidence | High for descriptive research and arithmetic checks. Lower for exact price outcomes because healthcare stocks can reprice around court rulings, approvals, trial data, and guidance. | High data confidence |
| Investment certainty | Medium certainty. JNJ is durable, but a buy decision depends on whether the investor accepts healthcare event risk at a premium valuation. | Medium |
JNJ AI stock forecast
JNJ AI Stock Forecast Scenarios
The JNJ AI stock forecast uses scenario math around the $267.24 quote and Johnson & Johnson 2026 adjusted EPS guidance midpoint near $11.55. The audited three-year framework produced a bearish area near $179, a base area near $286, and a bullish area near $393 before dividends.
Base case
$275 to $295
More likely if adjusted EPS compounds around mid single digits, Stelara pressure remains manageable, new product growth offsets losses of exclusivity, and the market values JNJ near a low-20s earnings multiple.
Bearish case
$170 to $190
More likely if patent erosion accelerates, litigation costs rise, MedTech separation distracts management, acquisitions underperform, or investors compress the multiple toward the high teens.
JNJ AI technical analysis
JNJ AI Technical Analysis
JNJ AI technical analysis is constructive but extended as of the July 8, 2026 cutoff. Investing.com reported a strong buy daily signal and a 14-day RSI near 65.7, while TipRanks listed JNJ above its 50-day simple moving average near $233.40 and 200-day simple moving average near $218.47.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $267.24 | Quote snapshot used for market cap math at the July 8, 2026 cutoff. |
| Near support | $264 to $267 | The latest quoted day range placed the low near $264.05 and the prior close near $267.24. |
| Near resistance | $269 to $270 | The latest quoted day range and 52-week high clustered near $269.43, making this a short-term resistance zone. |
| 50-day moving average | $233.40 | TipRanks listed the 50-day simple moving average as a buy signal on July 7, 2026. |
| 200-day moving average | $218.47 | The price remained well above the 200-day simple moving average, supporting the long-term trend. |
| Momentum | 14-day RSI about 65.7 to 67.8 | Investing.com and TipRanks readings showed positive momentum, but the setup was approaching overbought territory. |
| Volume | About 8.0 million recent shares | Johnson & Johnson investor stock info showed 8,000,739 shares on its referenced quote snapshot. |
| Volatility | Moderate large-cap healthcare volatility | Expect larger moves around earnings, court rulings, FDA decisions, clinical data, patent events, and separation updates. |
| Invalidation | Close below $264, then $233 | A decisive break below the near support zone would weaken the short-term setup. A break below the 50-day average would be a larger trend warning. |
JNJ AI trading strategy
JNJ AI Trading Strategy Framework
The JNJ AI trading strategy is a rules-based research framework for a durable healthcare stock trading near technical highs. It is not personal advice and should be paired with live quotes, filings, position sizing, and event checks.
Trend-following setup
Watch for JNJ to hold above the $264 to $267 support zone and clear the $269 to $270 resistance area with volume confirmation.
A close below $264 or a failed breakout after earnings should invalidate the short-term setup.
Mean-reversion setup
If JNJ pulls back toward the 50-day moving average without a new litigation, patent, or guidance problem, compare the selloff with oncology, neuroscience, and MedTech growth evidence.
Do not average down without a defined loss limit because healthcare event risk can turn a technical support level into a thesis break.
Fundamental monitor
Track Innovative Medicine sales, MedTech growth, Stelara erosion, Darzalex, Carvykti, Tremfya, Spravato, Caplyta, free cash flow, dividend coverage, litigation reserves, and orthopaedics separation milestones.
Reduce confidence if EPS growth depends mainly on one-time items, multiple expansion, or balance sheet leverage rather than durable product-level growth and cash conversion.
Investment research summary
Four-master Research Compression
Business essence
Johnson & Johnson converts scientific research, regulatory approval, physician adoption, hospital trust, and global distribution into recurring healthcare revenue across medicines and medical technology.
Moat
The moat is strongest where patents, clinical data, surgeon and prescriber familiarity, reimbursement access, and global scale reinforce each other. It narrows when exclusivity expires or a rival offers better efficacy, safety, workflow, or cost.
Munger risk inversion
The thesis fails if litigation costs stay open-ended, key medicines lose share faster than expected, pipeline assets disappoint, MedTech separation creates execution drag, or the market stops paying a premium multiple.
Management
Management has focused JNJ after the Kenvue separation and is now pursuing accelerated growth in six key businesses while balancing R&D, acquisitions, dividends, litigation, and the orthopaedics spin plan.
Industry trend
Healthcare benefits from aging demographics, chronic disease, oncology innovation, and less invasive procedures, but the industry faces payer pressure, patent cliffs, regulatory scrutiny, litigation, and binary clinical outcomes.
Valuation and margin of safety
JNJ is priced like a high-quality compounder, not a distressed healthcare name. Margin of safety depends on whether mid single digit EPS growth and legal risk containment justify a premium earnings multiple.
Source-backed data
JNJ Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| JNJ price | $267.24 | Investing.com and Google Finance quote snapshots | July 8, 2026 |
| Market capitalization | $643.30 billion, verified as $267.24 x 2.407216971 billion shares | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 2.407216971 billion from Fidelity, cross-checked against 2.409898936 billion in the 2025 Form 10-K filing date count | Fidelity and Johnson & Johnson 2025 Form 10-K | July 8, 2026 |
| FY2025 reported sales | $94.193 billion | Johnson & Johnson FY2025 results, SEC Form 10-K, Macrotrends, and StockAnalysis | July 8, 2026 |
| FY2025 net earnings | $26.804 billion | Johnson & Johnson FY2025 results and Macrotrends | July 8, 2026 |
| FY2025 free cash flow | About $19.7 billion | Johnson & Johnson FY2025 results and StockTitan cross-check | July 8, 2026 |
| Cash, cash equivalents and current marketable securities | $20.102 billion | Johnson & Johnson 2025 Form 10-K, Macrotrends, and StockTitan | July 8, 2026 |
| Long-term debt | About $39.4 billion | StockTitan and Johnson & Johnson 2025 Form 10-K debt note | July 8, 2026 |
| FY2025 segment sales | $60.401 billion Innovative Medicine and $33.792 billion MedTech | Johnson & Johnson 2025 Form 10-K segment table | July 8, 2026 |
| Q1 2026 sales and adjusted EPS | $24.062 billion sales and $2.70 adjusted diluted EPS | Johnson & Johnson Q1 2026 earnings release | July 8, 2026 |
| Updated 2026 guidance | $100.8 billion reported sales midpoint and $11.55 adjusted EPS midpoint | Johnson & Johnson Q1 2026 earnings release | July 8, 2026 |
| Technical indicators | Strong buy daily signal, RSI near 65.7, 50-day SMA near $233.40, 200-day SMA near $218.47 | Investing.com and TipRanks technical snapshots | July 8, 2026 |
Frequently Asked Questions
Compare ABBV AI stock analysisRead ABT AI stock forecastReview BSX AI technical analysisExplore Pineify AI Stock Picker
This JNJ AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Johnson & Johnson, or a guarantee of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if fundamentals, valuation, litigation, regulation, or market conditions change.